Plasma Exchange for Longevity: What the Human Trial Shows

Therapeutic plasma exchange has human research behind its longevity claims. That makes it worth examining carefully. It does not establish that paying for a series of exchanges will prevent disease, preserve independence or extend life. The useful question is whether the evidence connects a measurable blood change to a benefit a person can actually feel or experience.

Our assessment: an experimental longevity application of an established medical procedure. A lower biological-age score can justify further research; it cannot yet tell a healthy person how much benefit an invasive treatment will deliver. For the broader framework, see longevity medicine: what is proven.

Plasma exchange, plasmapheresis and young plasma are different

In therapeutic plasma exchange, or TPE, a machine separates blood cells from plasma, removes plasma, and returns the cells with replacement fluid. Replacement may use albumin solution or donor plasma, depending on the medical indication. This removes circulating substances rather than selectively identifying an “aging toxin.” Plasma also carries useful proteins, including antibodies and clotting factors.³

“Plasmapheresis” is sometimes used interchangeably with plasma exchange. It can also describe separating or collecting plasma, including donation. The word alone does not specify how much plasma is removed, what replaces it, or why the procedure is being performed.⁴ Those details matter when comparing research with a commercial package.

Infusing plasma collected from young donors is another intervention. It is not equivalent to exchanging a patient's plasma for albumin. The FDA warns that young-donor plasma has no proven clinical benefit for normal aging or memory loss and carries transfusion risks. That warning should not be presented as an evaluation of every albumin-exchange protocol; equally, a TPE study cannot validate young-plasma infusions.⁵

What the 2025 human study actually tested

Fuentealba and colleagues reported 44 enrolled participants, mostly healthy adults over 50, and 42 completers. Figure 1 lists analyzed groups of 10 receiving TPE plus intravenous immunoglobulin (IVIG), 11 receiving clustered TPE alone, 11 monthly TPE, and 10 sham controls. The main outcome was biological-age biomarkers, not clinical benefit.¹

The linked registry describes six procedures per active arm. Its schedules are clearer than the ambiguous labels “biweekly” or “bimonthly”: two exchanges within one week, repeated monthly, differs from one exchange every two weeks. IVIG is an additional antibody-containing medicine, not another name for albumin.²

The registry lists actual enrollment of 40, rather than the publication's 44. It was first posted in August 2024, after the recorded November 2023 primary completion. It labels allocation randomized and masking participant-only; the paper describes assignment by entry order, filling shorter schedules first.¹² This weakens confidence that treatment groups were comparable for reasons unrelated to treatment. A randomized label should not substitute for a convincing allocation method.

The registry also lists functional secondary outcomes, including grip strength and mobility. Listing an outcome is not reporting a successful result. Its status is currently unknown, with active-not-recruiting the last known status; the record was last updated in August 2024.² A dated registry entry cannot establish that follow-up has finished or that functional benefits have emerged.

What a younger clock result means

The strongest reported average clock change was a 2.61-year reduction with TPE plus IVIG. Some sham comparisons survived multiple-testing correction; within-group changes in individual clocks did not. Baseline clock differences complicate interpretation.¹

A number expressed in “years” feels intuitive. However, it is the output of a statistical model applied to a sample. It is not an amount of extra survival time credited to the participant. Nor does a blood-based score demonstrate that every organ became younger by the same amount.

The FDA distinguishes biomarkers from clinical endpoints: clinical endpoints measure how people feel, function or survive. Using a biomarker as a substitute requires evidence that changing it reliably predicts the relevant clinical benefit.⁶ Applied here, a study would need to connect treatment-induced clock changes with outcomes such as maintained function or fewer illnesses. An association between a clock and mortality in observational data does not, by itself, complete that connection.

This is why we do not convert the reported clock result into a projected lifespan gain or an annual rejuvenation rate. Repeating treatment also cannot be assumed to keep subtracting the same number of years. Our guides to biological-age tests and epigenetic clocks explain how to read these scores without treating them as a diagnosis.

What the comparison can and cannot establish

A sham procedure is more informative than comparing customers before and after treatment. It helps separate a treatment effect from repeated testing, attention and expectations. Here, the registry describes saline without circulating the participant's blood through the exchange machine.² That is an important control, although the allocation concerns still matter.

There is also a combination-treatment problem. If TPE with IVIG produces a stronger signal than TPE alone, that does not establish that plasma removal explains the difference. An IVIG-only comparison would help distinguish the contribution of the added medicine. Consequently, a clinic offering albumin exchange alone cannot simply borrow the best result from a combined protocol.

Our evidence rating remains provisional. Independent replication, transparent allocation and complete outcome reporting would be more persuasive than adding more molecular measurements to the same small sample. Many measurements from one participant are not equivalent to enrolling many independent participants.

Safety: read the denominator, not just the percentage

The abstract mentions two adverse-event discontinuations, one IVIG-related. The corrected safety section reports one mild allergic reaction in 240 procedures; methods restrict that count to completers.¹ These are different denominators and reporting frames. The low per-procedure percentage should not be read as the probability that a new patient will remain free of complications throughout a treatment course.

Clinical patient guidance identifies dizziness, calcium-related tingling from anticoagulation, allergic reactions and depletion of clotting factors as potential issues during plasma exchange. Venous access adds infection and bleeding risks.³⁷ The relevance of each depends on the replacement product, access method, underlying health and treatment schedule.

IVIG adds its own risk profile. FDA-hosted prescribing information for Bivigam includes boxed warnings for thrombosis, renal dysfunction and acute renal failure. This is evidence about the medicine class's important hazards, not proof that those events occurred in this longevity trial or an estimate of their frequency at its dose.⁸

Safety and benefit must be assessed together. Accepting procedural risk to treat a serious disease is a different decision from accepting it for an uncertain improvement in a test score. An established clinical use does not automatically establish a favorable benefit–risk balance for healthy customers.

Established treatment does not mean established anti-aging care

Plasma exchange has recognized disease-specific uses. For example, the FDA's discussion of plasma administration includes thrombotic thrombocytopenic purpura; NHS specialists describe exchange to remove harmful autoimmune antibodies.⁵⁷ Those indications have a defined clinical problem and a treatment objective. They do not validate generalized “blood cleaning” or age reversal.

Commercial relationships also deserve attention. The paper discloses Circulate affiliations for Kiprov, Verdin and Furman, and Furman's Edifice Health connection; it reports no specific funding.¹ The registry names Kiprov as sponsor and Circulate as collaborator.² These disclosures do not invalidate a finding. They make independent confirmation particularly valuable before a service is marketed as a dependable longevity intervention.

If a clinic cites this research, useful questions are concrete: Does its protocol match the studied schedule and replacement fluid? Does it include IVIG? Which outcomes have improved beyond blood tests? How are adverse events and people who stop treatment counted? What follow-up supports claims that benefits last? Our Fountain Life review provides broader context for evaluating expensive longevity programs; inclusion in a premium program does not raise an intervention's evidence level.

The current conclusion is narrower than age reversal: TPE has an early human biomarker signal, with substantial design and reporting limitations. A longer or healthier life from elective plasma exchange remains unproven. Better trials could change that conclusion. A compelling clock graphic cannot do so on its own.